|
|
|
Cardiac Diagnostic Technology |
| |
NewCardio Selected to Make Presentations at 32nd Annual
International Conference of the IEEE Engineering in Medicine and
Biology Society
Other topics:
Patient
Deductible Data,
Intensity-Modulated
Radiotherapy (IMRT),
Electronic Health Record
Jun 14, 2010
BUSINESS WIRE
Data Validates Effectiveness of CardioBip to Diagnose Acute
Cardiac Events
SANTA CLARA, Calif.,-- NewCardio, Inc., a cardiac diagnostic
technology provider, announced today that two of its recent
medical and technical submissions have been accepted for
presentation at the 32nd Annual International Conference of the
IEEE Engineering in Medicine and Biology Society conference. The
two papers: "Wireless Transmission of Reconstructed 12-Lead ECGs
in the Remote Monitoring of Atrial Fibrillation" and "Wireless
Remote Monitoring of Myocardial Ischemia Using Reconstructed
12-Lead ECGs" will be presented during the conference to be held
August 31st through September 4th, 2010, in Buenos Aires,
Argentina. |
| |
|
|
| |
NewCardio scientists
and their academic medical collaborators will present data from
two full clinical studies showing that CardioBip(TM) accurately
captured, wirelessly transmitted, and reconstructed full 12-lead
ECG data from two distinct patient groups: (1) patients with
coronary artery disease (CAD) with significant risk for
myocardial infarction, i.e. a heart attack, and (2) patients
with atrial fibrillation (AF), who are at significant risk for
stroke because of recurrent bouts of AF. CardioBip is a unique,
hand held device that provides for accurate and timely diagnoses
of acute cardiac events, and facilitates immediate intervention
in life-threatening situations -- even when the patient is far
removed from a medical care center. Images of the CardioBip are
available at www.newcardio.com/products-cardio-bip.php.
"This now marks the second very prestigious medical conference
that has accepted two of our papers for presentation this year.
The acceptance of these submissions reflects the growing
interest in telemedicine and the recognition that our science
and technology solutions are gaining acceptance in the industry
because of their quality and innovative nature, and because they
meet important and previously underserved needs," stated
NewCardio CEO Branislav Vajdic, PhD.
Medical experts increasingly recognize the need for long-term
outpatient monitoring of such patients, and the Company believes
the clinical study results that will be presented at the IEEE
Conference indicate that CardioBip is well-suited to fill this
unmet medical need.
The conference program will consist of plenary lectures,
symposia, workshops and invited sessions of the latest
significant findings and developments in all the major fields of
biomedical engineering. Submitted papers will be peer reviewed.
Accepted high quality papers will be presented in oral and
poster sessions, will appear in the Conference Proceedings and
will be indexed in PubMed/MEDLINE.
About NewCardio, Inc.
NewCardio is a cardiac
diagnostic and services company developing and marketing
proprietary software platform technologies to provide higher
accuracy to, and increase the value of, the standard 12-lead
ECG. NewCardio's 3-D ECG software platform reduces the time and
expense involved in assessing cardiac status while increasing
the ability to diagnose clinically significant conditions which
were previously difficult to detect. NewCardio's software
products and services significantly improve the diagnosis and
monitoring of cardiovascular disease, as well as cardiac safety
assessment of drugs under development. For more information,
visit www.newcardio.com. |
| |
|
|
| |
|
|
